Loading…
Cosmo Medical Spa was cited for unlawfully selling unapproved and misbranded compounded semaglutide drugs over the internet to U.S. consumers. The company's website falsely marketed compounded semaglutide products using FDA-approved drug names like "Ozempic," implying the compounded versions were equivalent to the approved medications, in violation of Federal Food, Drug, and Cosmetic Act sections 502(a) and 502(bb). This misrepresentation rendered the products misbranded and their introduction into interstate commerce a prohibited act under section 301(a) of the FDCA.